The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
LDN Social Media
Get connected with us on social networks
Atopic Dermatitis - Pamela Smith, MD, MS (2021 Conference) (LDN, low dose naltrexone)
Atopic dermatitis is a hereditary skin disorder, and the most common form of eczema. Dr. Smith reviews the pathophysiology and diagnostic criteria for atopic dermatitis, as well as some causes.
Mast Cell Activation Syndrome (MCAS) - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)
Leonard Weinstock, MD - Mast cell activation syndrome and potential role for LDN (2019 Conference) (LDN, low dose naltrexone)
Leonard Weinstock, MD discusses LDN for MCAS and SIBO at the LDN 2019 Conference. He discusses the etiology, symptoms, testing, and therapy for MCAS, SIBO, and POTS; and presents related cases.
Dana Keaton, ND - The scope of patient selection for LDN (2019 Conference) (LDN, low dose naltrexone)
Dr Leonard Weinstock, LDN Radio Show (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Dr Leonard Weinstock shares his Low Dose Naltrexone (LDN) experience on the LDN Radio Show with Linda Elsegood.
Dr Leonard Weinstock is from St Louis in Missouri and helps patients with GI Issues and other autoimmune conditions.
Dr John Kim, LDN Radio Show 07 Dec 2016 (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.
Linda Elsegood: Today we're joined by Dr John Kim. Thank you for joining us, John.
Dr John Kim: Well, thank you for the invitation, Linda,
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
BMJ Case Reports
January 2018
https://casereports.bmj.com/content/2018/bcr-2017-221405
Erythromelalgia in a Patient with Mast Cell Activation Syndrome: Response to Low Dose Naltrexone
Skin
08 May 2019
https://jofskin.org/index.php/skin/article/view/722
Erythromelalgia is a rare condition that may be associated with a variety of underlying conditions and is often refractory to therapy. We report a case of a patient with mast cell activation syndrome who developed erythromelalgia and responded to low dose naltrexone.